Alesta Therapeutics

Alesta Therapeutics is presented here only as a name submitted for brand enrichment. The supplied evidence consists of two Chinese-language news aggregation pages from 163.com (NetEase): one a daily business briefing covering China's national medical insurance plan, Unitree Robotics' listing and Samsung chip foundry pricing, and the other a commentary on China's new-energy vehicle market and second-tier luxury car brands. Neither page mentions Alesta Therapeutics, any pharmaceutical company of that name, its products, leadership, ownership, or history. Because the evidence does not support any factual claim about this entity, this dossier is intentionally minimal and flagged for review. No founding year, headquarters, founder, website, parent company, product pipeline, or market position has been asserted, since doing so would require fabrication. If Alesta Therapeutics is a genuine biopharmaceutical or therapeutics company, a dedicated official website, corporate registry filing, press release, or Wikipedia entry should be supplied as evidence before a full brand dossier can be written.

• 2026.08.20

  Reported2026.08.20

  BioMarin announces acquisition of Alesta Therapeutics for $275m upfront[3]BioMarin宣布以2.75亿美元预付款收购Alesta Therapeuticsbioxconomy.com

  BioMarin Pharmaceutical announced it will acquire Alesta Therapeutics for $275 million upfront plus up to $215 million in development and regulatory milestones, bringing the clinical-stage oral hypophosphatasia candidate ALE1 into its pipeline. The deal was approved by both boards, Alesta will spin out all non-ALE1 assets to a new entity before closing, and the transaction is expected to close this quarter subject to customary closing conditions.

Read more

1. 1【钛晨报】事关每个人看病报销，全民医保“十五五”规划发布；宇树科技上市首日收涨460%，京东也发布机器人战略；三星据悉上调芯片代...163.com
2. 2兵败如山倒！国产新能源或已证明：中国其实不需要二线豪华品牌163.com
3. 3BioMarin宣布以2.75亿美元预付款收购Alesta Therapeuticsbioxconomy.com